Patent Evaluation: Expression of M-CSF Deletion Mutant Polypeptides

Summary

Novelty: The construction of a recombinant vector suitable for the expression of modified monocytic colony stimulating factor (M-CSF) peptides is reported. On transformation into suitable animal cell hosts, these vectors are said to exhibit stable and sustained production of M-CSF active polypeptide.

Biology: The expression vector contains an M-CSF partial sequence amino acid from the N-terminus to 179, (including the M1-CSF signal sequence but not the amino acids from position 180 to the C-terminus). This sequence is positioned downstream of a suitable promoter such as the SV40 early promoter, and upstream of a dihydrofolate reductase gene marker (also under the control of the SV40 early promoter). Cells capable of high levels of expression of the modified M-CSF were selected by the use of methotrexate.